SEC Form 4 · accession 0001209191-19-001575
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Morneau
Officer — VP, Finance and Administration
Period of report
Jan 3, 2019
Accepted (ET)
Jan 3, 2019 · 8:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.58 | Jan 3, 2019 | A | 29,000 | A | Jan 3, 2020 | Jan 3, 2029 | Common Stock | 29,000 | 29,000 | D |
Explanation of responses
- F125% of the shares subject to the option will vest on each anniversary of the grant date.